Please assess the completion status of the following clinical trial:

Trial Title: Renal Function in Patients Submitted to Myocardial Revascularization Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* both sexes,~* aged from 18 to 75 years,~* submitted to revascularization surgery of the myocardium~* extracorporeal circulation,~* who had consented to participation by signing the Terms of Free and Clear Consent.~Exclusion Criteria:~* history of hepatic or renal dysfunction,~* history involving acute myocardial infarct~* patients that made use of vitamin C and E;~* patients presenting other cardiac pathologies (valvular, congenital, corrected or not in the same operational act).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 Isoflurane (Type: None): The first group (G1) will be submitted to inhalational general anesthesia with isoflurane (1 CAM, evaluated by expired concentration of isoflurane)
- 2 Propofol (Type: None): The second group (G2) to targeted venous general anesthesia controlled with propofol. The targeted concentration of propofol will be kept at the predicted plasma concentration from 1 to 2 µg.ml-1 by means of a Diprifusor® infusion pump. During the interval from 10 minutes preceding ECC initiation to 10 minutes after ECC, the propofol concentration will be increased to 2 or 3 µg.ml-

Based on this trial design, predict the completion outcome and termination type (if applicable).